A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Clinical trial NCT05469737 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05469737
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-14
- Primary completion
- 2028-07-31
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.